recent reports from these registries, it is interesting to note that in all worldwide studies, the lcSSc is by far the most predominant subset. The leading proportion varies from 73.3% in Australia to 56.6% in Pittsburgh (USA) and, averaging all the data among 19,781 patients, gives a value of 66.5% of lcSS as compared to 33.5% for the dcSSc (6-12) ( Fig. 1 ). It could be added that this reflects tertiary center practice which usually recruits a large group of patients but particularly the most severe. Therefore, one might argue that patients with mild form who may fulfill the 2013 classification criteria may not attend a tertiary hospital department which may lead to an overestimation of the proportion of dcSSc in the above studies. Whatever the limitations, the results are clear-cut and show that two-thirds of SSc patients, at least, fulfill the lcSSc criteria and this sub-group represents the highest subset.
Whatever the cutaneous subset, early diagnosis is a stake in any disease and discrepancies between the two subsets must be highlighted. Indeed, time from Raynaud's symptoms to diagnosis is thought to be shorter in dcSSc probably because of a more aggressive form. Differences regarding time to diagnosis have been recently highlighted by the Canadian network; among patients with dcSSc, the median time to diagnosis was 1.0 (interquartile range [IQR] 0.3-4.0) years after onset of Raynaud's phenomenon and 0.7 (0.2-1.9) years after onset of the first non-Raynaud's disease manifestation, whereas among patients with lcSSc, the median time to diagnosis was 4.5 (1.3-12.1) years after onset of Raynaud's phenomenon and 1.0 (0.2-4.3) years after onset of the first non-Raynaud's disease manifestation (13) . This means that more detailed and repeated examinations and potentially more tests might be required to facilitate the diagnosis in lcSSc and that there is room for improvement in early lcSSc.
Textbooks usually state that the phenotype of lcSSc is milder than that of dcSSc. Nevertheless, few studies of large sample size have specifically addressed this issue. With the support of worldwide bodies of doctors and of patients, we have performed a study to query the patients point of view about their illness. In the study we included two validated questionnaires to assess the quality of life. We recruited 1902 SSc patients with a mean age of 54 years, a mean disease duration of 9 years, taking into account the first non-Raynaud's symptom (14) . Using the Illness Perception Questionnaire-Revised (iPQR), it is noteworthy that the two subsets showed similar results with slightly more impact in the dcSSc subset for identity, daily life consequences and emotional being ( Fig. 2A ). Regarding SF36, a similar trend was observed with more severe consequences on both the physical and the mental components of the score but with mean values below 50 (considered for severe impairment) in the lcSSc subset for physical functioning, physical role, general health and vitality ( Fig. 2B ). Altogether these data support a much higher impact of the dcSSc regarding disability but the consequences of the lcSSc disease should not be neglected and are highly ranked by the patients.
In addition to the extent of skin fibrosis, one of the main difference between lcSSc and dcSSc is the frequency of organ involvement. The proportion of patients with major organ involvements during the course of the disease differs but also the time of occurrence (early involvement in the dcSSc) and the severity (more profound damages in dcSSc). Recent data have enlightened the degree and proportion of organ involve- ments in the two cutaneous subsets. Using the data coming from the "Eustar sex bias study" (7) , the comparisons of the frequency of organ involvements are reported in Table I . The results of the multivariable analyses show that male sex predominates in dcSSc, that gastro-intestinal symptoms occur similarly in both subsets, musculo-skeletal involvement is close in the two subsets with the exception of tendon friction rubs and joint contraction that are more common in dcSSc, but that digital ulcers, renal crisis and interstitial lung disease and in particular related restrictive syndrome predominate in dcSSc. Therefore, major organ involvements are more common in dcSSc but despite being less frequent, for example, digital ulcers were observed in 25% of lcSSc and lung fibrosis in 31% which means that major organ involvement is still a concern in these patients. In addition, with regards to the complains of the patients, Raynaud's phenomenon is equally distributed and musculo-skeletal involvement (pain, dexterousness) or gastro-intestinal involvement (reflux, satiety, bloating...), which are highly ranked with regards to disability (14) , are also found with a similar distribution in both cutaneous subsets. The results from other cohorts and databases confirm that major organ involvement should not be neglected in lcSS patients. Indeed, the Royal free experience based on a sample of their cohort with long-term follow-up (15) showed at inclusion that 68% of dcSSc patients had some degree of pulmonary fibrosis as compared to 44% in lcSSc patients. Over the entire follow-up period, 42% of dcSSc patients and 22% of lcSSc patients developed clinically significant pulmonary fibrosis. It is interesting to note that patients developed clinically significant lung fibrosis within the first 5 years in 34% for dcSSc as compared to 16% for lcSSc; this confirms that early investigations and monitoring are mostly important for dcSSc but that long-term follow-up is a priority for lcSSc. In a recent large multicenter Italian series (n = 821), lung involvement defined by bibasilar fibrosis at high resolution computerized tomography and/or restrictive lung disease on pulmonary function tests, has reported a prevalence of 53% in the lcSSc as compared to 74% in dcSSc patients at inclusion, further showing that although more common in the dcSSc, both subsets can be affected (16) . It is of interest to see that in the SLS2 study investigating oral immunosuppressants in interstitial lung disease with a primary outcome being forced vital capacity, 42% of the 142 included patients have a lcSSc (17) . It further highlights that lung involvement is a concern in both cutaneous subsets and that investigations should not be restricted to dc-SSc patients; this is important for clinical research and clinical trials, but also for routine management of the patients.
Lung vessel damages can promote pulmonary hypertension (PH) which is another key organ involvement in SSc patients. In the Royal Free Hospital scleroderma research database sample (15) , the earliest cases of PH were observed within the first 3 years from SSc onset, and subsequent incidence rates were 1%-2% per year. At 5 years, 5% of lcSSc patients and 4% of dcSSc patients had developed PH, while at 10 years the cumulative incidence was 15% for lcSSc patients and 13% for dcSSc patients. Over the entire follow-up period, 24% of lcSSc patients and 18% of dcSSc patients developed PH (p = 0.56). Although not significantly increased in the lcSSc subset, there is a trend for a higher risk in these patients. The frequency of PH is high in this latter cohort and other series showed a much lower prevalence, which might be explained by a referral bias. Indeed, the prevalence of precapillary PH in a multicenter study of SSc patients was calculated at 5% reaching 9% in meta-analysis (18) . Furthermore, in further reports, lcSSc was clearly identified as an independent risk factors for the development of PH. In the recent DETECT study looking at the best screening program to identify PH, in the non-PH group 36.5% of the patients fulfilled the dcSSc criteria and 54.3% the lcSSc criteria, whereas in the confirmed pulmonary arterial hypertension (PAH) group, 71% of the patients belonged to the lcSSc subset and 21% to the dcSSc, emphasizing a higher prevalence in lcSSc patients (19) . A recent meta-analysis investigated the survival of SSc-PH patients and was able to assemble a group of 2244 SSc-PH; the cutaneous subset was available for 1278 out of the whole group, and it is striking to see that 80% of this sample were lcSSc patients, further showing that this complication predominates in the lcSSc group (20) . Regarding survival, there was no difference according to cutaneous subset. Lung involvement is a strong contributor to death in SSc. In the Royal Free Hospital series of patients (15) , although in the first 5 years from SSc onset the survival rate was much lower for dcSSc patients than for lcSSc patients (85.5% vs. 94%), over subsequent years, annual survival rates became similar for the two subsets, suggesting that an overall worse survival for dcSSc patients is mainly due to high early mortality. Outcomes after 10 years have also been reported in a recent Italian multicenter study in which the 10-year survival rates were 77% in the dcSSc subset as compared to 81% in the lcSSc disease group (p = 0.03 for univariate comparison). Therefore, early disease-specific deaths may occur more commonly in dcSSc disease but thereafter survival seems to be similar at the long term.
Among the other aspects of clinical expression, polyautoimmunity is gaining interest with reproducible data showing that SSc patients commonly exhibit one or more concomitant auto-immune diseases. It is of note that this is more common in the lcSSc group. Indeed, in a meta-analysis we calculated that among 6102 patients, 26% had another autoimmune disease at the same time with thyroiditis and Sjogren's syndrome being the most common (21) . When we stratified the patients according to cutaneous subset we observed lcSSc subset in 82% of the poly-autoimmune patients as compared to 64% in the remaining (p<0.01) and this was particularly high for associated Sjogren's syndrome (80% of lcSSc) and for primary biliary cirrhosis (87%). This suggest that the autoimmune component and propensity might be particularly high for lcSSc but this will require dedicated investigations.
Beyond epidemiology and phenotype, another aspect to measure the importance of a disease in modern societies is to estimate the related costs. There are few studies in SSc per se, and even less comparing the impact of cutaneous subsets. However, a Hungarian study reported total annual costs of EUR12,093 for 20 dcSSc patients as compared to EUR8794 for lcSSc patients, the main difference being for total direct nonmedical costs (22) . A Canadian study showed within a larger sample size total costs of Can$16,135 for the year 2007 in lcSSc patients (n = 272) as compared to Can$21,708 in dcSSc patients (n = 185) (23) . Consistent with the above report, differences were not observed for diagnostic tests, medications acute-care hospitalizations and total direct costs but mainly for lost productivity and total indirect costs (23) .
Altogether these data show that lcSSc is the more prevalent subset occurring in about two-thirds of SSc patients. In addition, the new classification criteria will increase the proportion of this subset. Despite these numbers, the research is undoubtedly oriented toward the dcSSc group, with a key goal being to qualify a drug (such as an anti-fibrotic) by demonstrating its ability to prevent and/or reduce skin fibrosis in dcSSc patients. Nevertheless, as well as being numerous, the patients in the lcSSc subset exhibit a high burden with significant disability. It translates to an impairment in quality of life (QOL) that is only marginally lower than in dcSSc. Indeed, Raynaud's phenomenon, gastro-intestinal involvement and also musculoskeletal are very close when the two cutaneous subsets are compared. Furthermore, for major organ involvement, recent data show that lung fibrosis is not uncommon in lcSSc and that pulmonary hypertension is clearly more common in lcSSc patients. Therefore, a systematic screening is also required for lcSSc despite some feeling that it is a benign disease, and in contrast to the dcSSc the long-term outcomes are probably even more important and require adherence of the patients to long-term follow-up programs.
On a research agenda, it will be important to better describe skin involvement in lcSSc because if a drug is qualified in dcSSc, its potential use in at least a part of lcSSc patients will have to be addressed. Following similarities between the two subsets, if a drug is envisaged as a disease-modifying agent for SSc, its assessment in lcSSc will have to be performed and shared outcome measures will have to be proposed. One might suggest that QOL may be instrumental in measuring the overall effects of a SSc disease-modifying antirheumatic drug (DMARD). It is also expected that the timelines of organ involvements for lcSSc will be clarified thanks to all the ongoing registries and the possibility to work on a very large sample size.
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